Opioids exert their effects by binding to and activating the μ-opioid receptor. This occurs because opioids structurally mimic endogenous endorphins which are naturally found within the body and also work upon the μ-opioid receptor set. The way in which opioids structurally mimic these natural endorphins results in their euphoria, pain relief and anxiolytic effects. This is because endorphins are responsible for reducing pain, causing sleepiness, and feelings of pleasure. They can be released in response to pain, strenuous exercise, orgasm, or general excitement. The bioavailability of orally administered methadone can vary from 40% to around 99%. Methadone is metabolized by the cytochrome P450 system.
Unlike most opioids, methadone is a weak serotonin reuptake inhibitor as well as a weak NMDA antagonist. Similarly to dextropropoxyphene, methadone is a nicotinic acetylcholine receptor antagonist.
The metabolic half life of methadone differs from its duration of action. The metabolic half life is 8 to 59 hours (approximately 24 hours for opioid-tolerant people, and 55 hours in opioid-naive people), as opposed to a half life of 1 to 5 hours for morphine. The length of the half life of methadone allows for exhibition of respiratory depressant effects for an extended duration of time in opioid-naive people.
Levomethadone (the L enantiomer) is a μ-opioid receptor agonist with higher intrinsic activity than morphine, but lower affinity. Dextromethadone (the S enantiomer) does not affect opioid receptors but binds to the glutamatergic NMDA (N-methyl-D-aspartate) receptor, and acts as an antagonist against glutamate. Methadone has been shown to reduce neuropathic pain, primarily through NMDA receptor antagonism. Glutamate is the primary excitatory neurotransmitter in the central nervous system. Acting as an NMDA antagonist may be one mechanism by which methadone decreases craving for opioids and tolerance, and has been proposed as a possible mechanism for its distinguished efficacy regarding the treatment of neuropathic pain.
Methadone also acted as a potent, noncompetitive α3β4 neuronal nicotinic acetylcholine receptor antagonist in rat receptors, expressed in human embryonic kidney cell lines.
Dextromethadone:
- Mu opioid agonist - 24.8 nM
- Kappa opioid agonist - 543 nM
- Delta opioid agonist - 1674 nM
According to a study published in the Journal of Pharmacology and Experimental Therapeutics, the dissociation constants (Kd) of Levomethadone at the different opioid receptors are as follows:
- Mu opioid agonist - 2.5 nM
- Kappa opioid agonist - 54 nM
- Delta opioid agonist - 97nM
moderate toxicity relative to dose. As with all opioids, long-term effects can vary but can include diminished libido, apathy and memory loss. It is also lethal when mixed with depressants like alcohol or benzodiazepines]] and generally has a wider range of substances which it is dangerous to combine with in comparison to other opioids. Methadone is known to lower the seizure threshold. It should not be taken during benzodiazepine withdrawals as this can potentially cause seizures.
It is strongly recommended that one use harm reduction practices when using this drug.
As with other opioids,extremely addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal symptoms may occur if a person suddenly stops their usage.develops with prolonged and repeated use. The rate at which this occurs develops at different rates for different effects, with tolerance to the constipation-inducing effects developing particularly slowly for instance. This results in users having to administer increasingly large doses to achieve the same effects. After that,3 - 71 - 2 weeks to be back at baseline (in the absence of further consumption). Methadone presents cross-tolerance with Cross-all other opioids, meaning that after the consumption of methadone all opioids will have a reduced effect.
The risk of fatal opioid overdoses rise sharply after a period of cessation and relapse, largely because of reduced tolerance. To account for this lack of tolerance, it is safer to only dose a fraction of one's usual dosage if relapsing. It has also been found that the environment one is in can play a role in opioid tolerance. In one scientific study, rats with the same history of heroin administration were significantly more likely to die after receiving their dose in an environment not associated with the drug in contrast to a familiar environment.
- Psychedelics** - Methadone is known to lower the seizure threshold and psychedelics may act as triggers for seizures in those who are susceptible to them.
- Serotonin syndrome risk
While methadone has been reported to occasionally cause serotonin syndrome when combined with certain substances (such as those listed below), anecdotal reports suggests that it does so at a much lower rate than tramadol.
Canada:** Methadone is a Schedule I Controlled Substance.
Germany:** Methadone is a controlled substance under Anlage III of the BtMG. It can only be prescribed on a narcotic prescription form.
Russia:** Methadone is a Schedule I controlled substance.
Switzerland: Methadone is a controlled substance specifically named under Verzeichnis A. Medicinal use is permitted.
United Kingdom:** Methadone is a Class A, Schedule 2 drug in the United Kingdom.
United States:** Methadone is a Schedule II Controlled Substance.
Responsible use
Opioid
Tramadol
Fentanyl
Dextropropoxyphene
Methadone (Wikipedia)
Methadone (Erowid Vault)
Methadone (Isomer Design)
Methadone (DrugBank)
Methadone (Drugs.com)
Methadone (Drugs-Forum)
Methadone can be administered via oral. The route of administration can influence both the onset and intensity of decreased libido.